Poziotinib had low clinical activity in acquired resistant NSCLC, including in patients that carried T790M mutations69, and poziotinib recently failed to meet a primary endpoint in a clinical trial focused on EGFR exon 20 mutation70,71. This evidence concerns the gene EGFR and non-small cell lung carcinoma.